Evidence map›Paper›PMID 33837835›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2021

The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up.

Mattis Bertlich, Clemens Stihl, Enzo Lüsebrink, Johannes C Hellmuth, Clemens Scherer, Saskia Freytag, Jennifer Lee Spiegel, Ivelina Stoycheva, Martin Canis, Bernhard G Weiss and 2 more

Open access · hybridAbstract read
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Smell and Taste Function and Their Disturbances in Sjögren's Syndrome.International journal of environmental research and public health · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Mattis BertlichDepartment of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany.ORCID http://orcid.org/0000-0002-6479-5899
Clemens StihlDepartment of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
Enzo LüsebrinkMedizinische Klinik und Poliklinik I, University Hospital, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
Johannes C HellmuthMedizinische Klinik und Poliklinik III University Hospital, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
Clemens SchererMedizinische Klinik und Poliklinik I, University Hospital, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
Saskia FreytagEpigenetics and Genomics Division, Harry Perkins Institute of Medical Research, Nedlands, WA, Australia.
Jennifer Lee SpiegelDepartment of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
Ivelina StoychevaDepartment of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
Martin CanisDepartment of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
Bernhard G WeissDepartment of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
Friedrich Ihler *Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany. Friedrich.Ihler@med.uni-muenchen.de.
Frank Haubner *Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
Ludwig-Maximilians-Universität München · DEHarry Perkins Institute of Medical Research · AULMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIt has been established that the infection with SARS-CoV-2 may cause an impairment of chemosensory function. However, there is little data on the long-term effects of SARS-CoV-2 infection on chemosensory function.

methodsTwenty three SARS-CoV-2-positive patients diagnosed in spring 2020 with subjective hyposmia (out of 57 positive patients, 40.3%) were compared to SARS-CoV-2-positive patients without hyposmia (n = 19) and SARS-CoV-2-negative patients (n = 14). Chemosensory function was assessed by the Brief Smell Identification Test (BSIT), Taste Strips (TS), Visual Analogue Scales (VAS), and the SNOT-22. The initial cohort with hyposmia were also examined at 8 weeks and 6 months after initial examination.

resultsThere were no differences between the SARS-CoV-2-positive cohort without hyposmia and negative controls in terms of BSIT (8.5 ± 2.6 vs. 10.2 ± 1.8), TS (3.4 ± 0.6 vs. 3.9 ± 0.3) or VAS (2.1 ± 1.3 vs. 1.1 ± 0.5); yet the SNOT-22 was significantly elevated (27.7 ± 11.2 vs. 16.4 ± 10.8). The SARS-CoV-2-positive group with hyposmia performed significantly poorer in BSIT (4.0 ± 1.7 vs. 8.5 ± 2.6/10.2 ± 1.8), TS (2.6 ± 1.3 vs. 3.4 ± 0.6/3.9 ± 0.3), and VAS (7.9 ± 2.2 vs. 2.1 ± 1.3/1.1 ± 0.5) compared to both control groups. At week 8 and month 6 control, six and five patients, respectively, still suffered from subjectively and objectively impaired chemosensory function. The other patients had recovered in both respects.

conclusionSARS-CoV-2 patients with subjectively impaired chemosensory function regularly perform poorly in objective measurements. About 70% of patients suffering from olfactory dysfunction in SARS-CoV-2 quickly recover-the rest still suffers from considerable impairment 6 months after infection.

Indexed as

COVID-19Olfaction DisordersFollow-Up StudiesHumansSARS-CoV-2SmellTaste DisordersAnosmiaChemosensory dysfunctionCoronavirusCOVID-19HyposmiaSARS-CoV-2Smell training

Identifiers

PMID33837835
PMCPMC8035606
OpenAlexW3145281108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.